Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sanofi
Imunon
UNICANCER
University of Chicago
Nektar Therapeutics
NSABP Foundation Inc
Takeda
Hoffmann-La Roche
UroGen Pharma Ltd.
Ipsen
ChineseAMS
Steba Biotech S.A.
Queensland Centre for Gynaecological Cancer
Amgen
Novartis
University College, London
Novartis
Oncolytics Biotech
AstraZeneca
National Institutes of Health Clinical Center (CC)
Janssen-Ortho Inc., Canada
Vical